Proven programs help companies stay visible, engage high-value buyers, and deliver measurable ROI - even in a downturn LONDON, April…
Non-human primate pharmacokinetics data suggests IBIO-600, a potentially best-in-class long-acting anti-myostatin antibody, could have a human half-life as long as…
Sanofi to acquire Dren Bio’s bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline Dren Bio deep B-cell…
February 23, 2025 12:07 ET | Source: IO Biotech • Findings support the development of a novel peptide vaccine targeting…
Anthos Therapeutics is a clinical-stage biopharmaceutical company developing abelacimab, a potential first-in-class monoclonal antibody targeting the FXI inhibition pathwayAbelacimab is…
January 15, 2025 16:05 ET | Source: Solid Biosciences Inc. - Duchenne: Dosed four patients in INSPIRE DUCHENNE clinical trial;…
MEDIA RELEASE Strong first year as standalone company; global leader Sandoz uniquely positioned in attractive and growing USD 200 billion…
Vivoryon Therapeutics N.V. Provides R&D-Update Further Strengthening Development Pipeline in Kidney Disease A meta-analysis of VIVIAD and VIVA-MIND1 data confirmed…
Ad hoc announcement pursuant to Art. 53 LR Mid-term sales guidance upgraded to +6% CAGR 2023-2028 and +5% 2024-2029Strong momentum…
